In vitro characterization of SLV308 (7‐[4‐methyl‐1‐piperazinyl]‐2(3H)‐benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5‐HT1A receptor agonist

@article{Glennon2006InVC,
  title={In vitro characterization of SLV308 (7‐[4‐methyl‐1‐piperazinyl]‐2(3H)‐benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5‐HT1A receptor agonist},
  author={Jeffrey C. Glennon and Guus van Scharrenburg and Eric Ronken and Mayke B. Hesselink and Jan Hendrik Reinders and Martina A W van der Neut and Stephen K. Long and Rolf W. Feenstra and Andrew C McCreary},
  journal={Synapse},
  year={2006},
  volume={60}
}
Present Parkinson's disease treatment strategies are far from ideal for a variety of reasons; it has therefore been suggested that partial dopamine receptor agonism might be a potential therapeutic approach with potentially fewer side effects. In the present study, we describe the in vitro characterization of the nonergot ligand SLV308 (7‐[4‐methyl‐1‐piperazinyl]‐2(3H)‐benzoxazolonemonohydrochloride). SLV308 binds to dopamine D2, D3, and D4 receptors and 5‐HT1A receptors and is a partial… 
View on Wiley
ncbi.nlm.nih.gov
37 Citations
Highly Influential Citations
2
Background Citations
10
Methods Citations
1
Results Citations
3

37 Citations

Citation Type

Citation Type

An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease
Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson's Disease or Schizophrenia.
The effect of methoxy and hydroxy substitutions in different positions of the phenoxy moiety of the N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-phenoxyethan-1-amine scaffold on the affinity/activity…
In vivo effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5‐HT1A receptor agonist, on rat dopamine and serotonin neuronal activity
TLDR
The present study shows that pardoprunox acts in the VTA as a potent partial D2‐like receptor agonist reducing preferentially the burst activity linked to the phasic activity of DA neurons.
Synthesis and Biological Evaluation of a Series of Novel 1-(3-((6-Fluoropyridin-3-yl)oxy)propyl)piperazines as Dopamine/Serotonin Receptor Agonists
TLDR
Twenty novel 1-(3-((6-fluoropyridin-3-yl)oxy)propyl)piperazine derivatives were designed and synthesized using a bioisosterism approach, and the results showed that several compounds exhibited a multitarget combination of D2/5-HT1A agonism.
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
  • M. Millan
  • Biology, Psychology
    Pharmacology & therapeutics
  • 2010
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
TLDR
Results suggest that 5-HT(1A) and D(2) dual-receptor agonist (-)-15 may present a novel candidate drug in the treatment of PD and LID.
Synthesis, Pharmacological Characterization and QSAR Modelling of 4-Phenylpiperidines and 4-Phenylpiperazines Effects on the dopaminergic neurotransmission in vivo
TLDR
It is primarily interactions with these two targets that lead to the in vivo response observed for this class of compounds, and a strong correlation between the affinities to the D2 receptor and to MAO A and the levels of the metabolite DOPAC in striatum has been established.
Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1.
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets
Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets
TLDR
The results suggest that the partial D2 agonist pardoprunox (SLV308) is less likely to prime for dyskinesia or to lead to the expression of dysKinesia than either levodopa or full dopamine agonists.
...
1
2
3
4
...

References

SHOWING 1-10 OF 39 REFERENCES
In vivo characterization of novel full and partial 2-(4-aminophenyl)-N,N-dipropylethylamine dopamine D(2) receptor agonists.
The Serotonin1A Receptor Partial Agonist S15535 [4-(Benzodioxan-5-yl)1-(indan-2-yl)piperazine] Enhances Cholinergic Transmission and Cognitive Function in Rodents: A Combined Neurochemical and Behavioral Analysis
TLDR
S15535 reinforces frontocortical and hippocampal release of acetylcholine and displays a broad-based pattern of procognitive properties, which are consistent with previous work on cholinergic transmission and cognitive function in rodents.
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
TLDR
S33084 is a novel, potent, selective, and competitive antagonist at hD(3)-receptors that tonically inhibit ascending dopaminergic pathways, although the latter may contribute to phasic suppression of DA release in frontal cortex.
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
TLDR
H5-HT(2C) receptors couple to both Gq/11 and Gi(3) in CHO cells, and efficacy for G protein subtype activation is both ligand- and receptor reserve-dependent, as determined by a guanosine 5'-O-(3-[(35)S]GTPgammaS]thio)triphosphate binding assay.
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
TLDR
The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D(3) receptors may benefit the treatment of schizophrenia.
Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease
  • L. Metman, V. Sethy, T. Chase
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 1994
TLDR
The results suggest that partial dopamine agonists can exert agonist or antagonist activity in parkinsonian patients depending on concurrent dopaminergic tone and that this class of agents may have relatively limited clinical utility.
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
TLDR
The data suggest that hD3 receptors may couple to Galphaq/alpha11 and would be consistent with the observation that pertussis toxin pretreatment, which inactivates only Gi/o proteins, only submaximally blocked dopamine-stimulated [35S]GTPgammaS binding in CHO-hD3 cells.
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors
TLDR
These results, together with previous studies demonstrating partial agonist activity at serotonin 5-hydroxytryptamine (5-HT)1A receptors and antagonist activity at 5-HT2A receptors, support the identification of aripiprazole as a dopamine-serotonin system stabilizer.
Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile
TLDR
Sarizotan at higher doses decreased DA precursor accumulation in reserpinized rats and induced contralateral rotational behavior in unilaterally substantia nigra lesioned rats, indicating some intrinsic dopaminergic activity.
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor
TLDR
In conclusion, antiparkinson agents display diverse agonist and antagonist properties at multiple subtypes of D2-like receptor and α1/α2-AR, actions, which likely contribute to their contrasting functional profiles.
...
1
2
3
4
...